Optimizing the Use of Immunotherapy in the First-line Maintenance Setting for Metastatic Urothelial Carcinoma
Guest: Petros Grivas, MD, PhD
\n\n Guest: Thomas Powles, MD, PhD
\n\n\n \n
Survival for patients with metastatic urothelial cancer has increased with the approval of immune therapy, antibody-drug conjugates, and targeted agents. In the maintenance setting, avelumab has become the global standard of care. Do you know how to evaluate and effectively implement immune therapy in the maintenance setting in your practice?